Search

everythinglearnresearchcommunity

for

Search:↓

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

MK-5108 is safe and shows potential against tumors, especially alone.

Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

Bicalutamide may effectively treat female pattern hair loss with minimal side effects.

Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.

Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.

LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.

Flutamide helps with prostate cancer and some skin conditions but can harm the liver.

The method accurately and quickly measures silodosin and dutasteride in mixtures.

Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

The drug combination was safe and showed promise in treating advanced tumors.

A fast and accurate method was developed to measure alfuzosin and dutasteride in human plasma.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.

Bicalutamide improves hair density in women safely.

CTP-543 is generally safe for treating alopecia areata.

Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Weekly bicalutamide is safe and effective, with 50 mg/week recommended.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.

Flutamide rarely causes liver toxicity in prostate cancer patients.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.